Cencora Raises 2025 Profit Forecast Amid Strong Specialty Drug Demand
Cencora Raises 2025 Profit Forecast Amid Strong Specialty Drug Demand

Cencora Raises 2025 Profit Forecast Amid Strong Specialty Drug Demand

News summary

Cencora, formerly known as AmerisourceBergen, reported a significant revenue increase of 12.8% year-over-year for the first quarter of fiscal 2025, reaching $81.5 billion, driven by strong sales of specialty medicines and GLP-1 drugs. The company raised its adjusted earnings per share (EPS) guidance for the year to a range of $15.25 to $15.55, reflecting robust performance and strategic acquisitions, including Retina Consultants of America. Despite a decrease in GAAP diluted EPS due to operating costs, Cencora's adjusted EPS of $3.73 exceeded analyst expectations of $3.50. The U.S. healthcare solutions segment saw a notable 14% revenue gain, bolstered by increased demand for medications addressing complex conditions. Cencora's focus on specialty services and customer-centric strategies has positioned it favorably in the healthcare market. Analysts remain optimistic about Cencora's growth potential, with projected revenue growth of 8% to 10% for the full fiscal year.

Story Coverage
Bias Distribution
67% Center
Information Sources
daae85f0-2883-42fc-b085-888140adf30da3544a73-dab3-486d-ae75-bd4d15f01f5598605d3a-f647-49a6-87c7-2db995124a5a
Left 33%
Center 67%
Coverage Details
Total News Sources
3
Left
1
Center
2
Right
0
Unrated
0
Last Updated
3 days ago
Bias Distribution
67% Center
Related News
Daily Index

Negative

22Serious

Neutral

Optimistic

Positive

Ask VT AI
Story Coverage

Related Topics

Subscribe

Stay in the know

Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Present

Gift Subscriptions

The perfect gift for understanding
news from all angles.

Related News
Recommended News